ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
0 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
562
|
250K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
11 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
562
|
250K
|
11
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
2 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
562
|
250K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
6 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
562
|
250K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Annual Report to shareholders
|
|
TripAces
|
194 |
75K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
194
|
75K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Annual Report to shareholders
|
|
TripAces
|
194 |
75K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
194
|
75K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Kidney Disease Drug Candidate Progressing to Human Trials
|
|
TripAces
|
28 |
9.9K |
6 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
28
|
9.9K
|
6
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Kidney Disease Drug Candidate Progressing to Human Trials
|
|
TripAces
|
28 |
9.9K |
34 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
28
|
9.9K
|
34
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.6M |
1 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
10K
|
4.6M
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.6M |
6 |
21/04/24 |
21/04/24 |
ASX - By Stock
|
10K
|
4.6M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.6M |
19 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
10K
|
4.6M
|
19
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
15 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
562
|
250K
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Upcoming Phase 2 Trial Announcement Dates
|
|
TripAces
|
7 |
3.9K |
2 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
7
|
3.9K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Results webinar
|
|
TripAces
|
130 |
63K |
18 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
130
|
63K
|
18
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Results webinar
|
|
TripAces
|
130 |
63K |
1 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
130
|
63K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Results webinar
|
|
TripAces
|
130 |
63K |
8 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
130
|
63K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
980 |
495K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
980
|
495K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
980 |
495K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
980
|
495K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
4 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
562
|
250K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Comment on research report
|
|
TripAces
|
316 |
162K |
3 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
316
|
162K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
3 |
17/02/24 |
17/02/24 |
ASX - By Stock
|
562
|
250K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Comment on research report
|
|
TripAces
|
316 |
162K |
3 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
316
|
162K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
5 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
562
|
250K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.6M |
5 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
10K
|
4.6M
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.6M |
28 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
10K
|
4.6M
|
28
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
23 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
562
|
250K
|
23
|
|
ASX - By Stock
|
NEU |
Re:
Merck to acquire Prometheus in a US$ 10.8 b deal
|
|
TripAces
|
107 |
62K |
7 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
107
|
62K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.6M |
21 |
28/01/24 |
28/01/24 |
ASX - By Stock
|
10K
|
4.6M
|
21
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
6 |
25/01/24 |
25/01/24 |
ASX - By Stock
|
562
|
250K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
16 |
25/01/24 |
25/01/24 |
ASX - By Stock
|
562
|
250K
|
16
|
|
ASX - By Stock
|
NEU |
Re:
Jefferies Role
|
|
TripAces
|
9 |
4.3K |
29 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
9
|
4.3K
|
29
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
980 |
495K |
16 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
980
|
495K
|
16
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
980 |
495K |
2 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
980
|
495K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
980 |
495K |
9 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
980
|
495K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
980 |
495K |
23 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
980
|
495K
|
23
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
980 |
495K |
14 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
980
|
495K
|
14
|
|
ASX - By Stock
|
NEU |
Re:
The NDD box seat
|
|
TripAces
|
13 |
9.2K |
21 |
16/01/24 |
16/01/24 |
ASX - By Stock
|
13
|
9.2K
|
21
|
|
ASX - By Stock
|
NEU |
Re:
Potential Takeover
|
|
TripAces
|
121 |
53K |
6 |
15/01/24 |
15/01/24 |
ASX - By Stock
|
121
|
53K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Potential Takeover
|
|
TripAces
|
121 |
53K |
24 |
15/01/24 |
15/01/24 |
ASX - By Stock
|
121
|
53K
|
24
|
|
ASX - By Stock
|
NEU |
Re:
Potential Takeover
|
|
TripAces
|
121 |
53K |
22 |
13/01/24 |
13/01/24 |
ASX - By Stock
|
121
|
53K
|
22
|
|
ASX - By Stock
|
NEU |
Re:
Potential Takeover
|
|
TripAces
|
121 |
53K |
14 |
13/01/24 |
13/01/24 |
ASX - By Stock
|
121
|
53K
|
14
|
|
ASX - By Stock
|
EUR |
Re:
Ann: NASDAQ Listing Update
|
|
TripAces
|
155 |
46K |
0 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
155
|
46K
|
0
|
|
ASX - By Stock
|
EUR |
Re:
Ann: NASDAQ Listing Update
|
|
TripAces
|
155 |
46K |
0 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
155
|
46K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
562 |
250K |
23 |
09/01/24 |
09/01/24 |
ASX - By Stock
|
562
|
250K
|
23
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
980 |
495K |
10 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
980
|
495K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Ann: P2 trial shows significant improvements in Phelan-McDermid
|
|
TripAces
|
208 |
85K |
10 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
208
|
85K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
TripAces
|
315 |
156K |
12 |
17/12/23 |
17/12/23 |
ASX - By Stock
|
315
|
156K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
TripAces
|
315 |
156K |
8 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
315
|
156K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.6M |
2 |
13/12/23 |
13/12/23 |
ASX - By Stock
|
10K
|
4.6M
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
677 |
321K |
12 |
13/12/23 |
13/12/23 |
ASX - By Stock
|
677
|
321K
|
12
|
|